Key result
Subcutaneous adipose tissue visfatin is highly expressed in lean, insulin-sensitive subjects and attenuated in those with high intramyocellular lipids, low insulin sensitivity, and high inflammation.
Why the study?
Does visfatin expression correlate with insulin sensitivity, intramyocellular lipids, and inflammation in humans?
Observational
Does visfatin expression correlate with insulin sensitivity, intramyocellular lipids, and inflammation in humans?
Subcutaneous adipose tissue visfatin is highly expressed in insulin-sensitive subjects and attenuated in those with high intramyocellular lipids and inflammation, while visceral and subcutaneous visfatin are oppositely regulated by BMI.
No takes yet. Share an insight, caveat, or question.
Visfatin adipose expression shows depot-specific links to BMI and insulin sensitivity; leaves open its metabolic role pending prospective studies.
Varma et al. (2006) conducted an observational in Normal or impaired glucose tolerance. Visfatin expression was evaluated on Relationship between visfatin and obesity, insulin sensitivity, adipose tissue inflammation, intramyocellular lipids, and response to insulin sensitizers. Subcutaneous adipose tissue visfatin is highly expressed in lean, insulin-sensitive subjects and attenuated in those with high intramyocellular lipids, low insulin sensitivity, and high inflammation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: